Deok-Bog Moon

Deok-Bog Moon

Auto-generated profile, based on publicly available information

Deok-Bog Moon

Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HKHyung-Don Kim
Hyung-Don Kim
SJSeyoung Jung
Seyoung Jung
HLHo Yeong Lim
Ho Yeong Lim
BRBaek-Yeol Ryoo
Baek-Yeol Ryoo
MRMin-Hee Ryu
Min-Hee Ryu
CYChanghoon Yoo
Changhoon Yoo
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib–nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). ORR per RECIST version 1.1 was 31.0%, meeting the primary endpoint. The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%). Median PFS was 7.38 months. The 1-year OS rate was 80.5%, and the median OS was not reached. Exploratory single-cell RNA sequencing analyses of peripheral blood mononuclear cells showed that long-term responders exhibited T cell receptor repertoire diversification, enrichment of genes representing immunotherapy responsiveness in MKI67+ proliferating CD8+ T cells and a higher probability of M1-directed monocyte polarization. Our data support further clinical development of the regorafenib–nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709.

3 January 2023 in Hepatology
Verified
Journal Article
Closed access
HJHyehyun Jeong
Hyehyun Jeong
KKKyu-pyo Kim
Kyu-pyo Kim
JJJae Ho Jeong
Jae Ho Jeong
DHDae Wook Hwang
Dae Wook Hwang
Jae Hoon LeeJae Hoon Lee
Jae Hoon Lee
CYChanghoon Yoo
Changhoon Yoo
Background and Aims: The effectiveness of gemcitabine-based adjuvant chemotherapy is unclear in cholangiocarcinoma. We investigated the role of adjuvant gemcitabine plus cisplatin (GemCis) in a homogeneous group of high-risk patients with resected, lymph node–positive extrahepatic cholangiocarcinoma. Approach and Results: Adenocarcinoma of perihilar or distal bile duct with regional lymph node metastasis who underwent curative-intent surgery (R0/R1) was eligible. Patients were randomized to receive GemCis (gemcitabine 1000 mg/m2, cisplatin 25 mg/m2 on days 1 and 8) or capecitabine (1250 mg/m2 twice daily on days 1–14) every 3 weeks for 8 cycles. Primary endpoint was disease-free survival. Secondary endpoints were overall survival and safety. All p values are 1 sided and were considered significant if <0.1. Between July 2017 and November 2020, 101 patients (50 in the GemCis and 51 in the capecitabine group) were included in the intention-to-treat population. Perihilar and distal bile ducts were the primary sites in 45 (44.6%) and 56 (55.4%) patients, respectively, and 32 (31.7%) had R1 resections. Median (1-sided 90% CI) follow-up duration was 33.4 (30.5–35.8) months. In the GemCis and capecitabine group, 2-year disease-free survival rates were 38.5% (29.5%–47.4%) and 25.1% (17.4%–33.5%) [HR=0.96 (CI, 0.71–1.30), p=0.430], and median overall survival was 35.7 months (29.5–not estimated) and 35.7 months (30.9–not estimated) [HR=1.08 (CI, 0.71–1.64), 1-sided p=0.404], respectively. Grade 3–4 adverse events occurred in 42 (84.0%) and 8 patients (16.0%) in the GemCis and capecitabine groups, respectively. No treatment-related deaths were reported. Conclusions: In resected lymph node–positive extrahepatic cholangiocarcinoma, adjuvant GemCis did not improve survival outcomes compared with capecitabine.

1 December 2016 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Closed access
PDF file
SKSeok-Hwan Kim
Seok-Hwan Kim
DMDeok-Bog Moon
Deok-Bog Moon
WKWan-Joon Kim
Wan-Joon Kim
WKWoo-Hyoung Kang
Woo-Hyoung Kang
JKJae Hyun Kwon
Jae Hyun Kwon
SLSung-Gyu Lee
Sung-Gyu Lee
Background: Adult living donor liver transplantation (LDLT) is one of the best treatments for hepatocellular carcinoma (HCC). However, when recurrence of HCC after LDLT occurs, the prognosis is poor because of rapid progression. Preoperative level of α-fetoprotein (AFP) and protein induced by vitamin K antagonist-II (PIVKA-II) reportedly correlate with recurrence of HCC after LDLT. Methods: We examined AFP and PIVKA-II preoperatively as predictors of HCC recurrence in 461 patients who underwent LDLT using right liver graft for HCC from May 2007 to December 2013. Results: Among these, 77 patients (16.7%) who experienced recurrence were retrospectively reviewed. Multivariate analysis revealed tumor size >5 cm, AFP >150 nag/mol and PIVKA-II >100 maul/mol as significant independent risk factors for recurrence. The median time to recurrence was 10 months. The median survival time after recurrence was 26 months, and the 1-, 3- and 5-year survival rates after recurrence were 80.5%, 58%, and 28.3% respectively. Conclusions: Preoperatively, not only morphology of the tumor but also AFP and PIVKA-II levels can offers important information for the recurrence after LDLT for HCC. Thus, combination of tumor markers might be used for expansion of pre-existing strict selection criteria of liver transplantation for HCC.

3 February 2019 in Transplant International
Verified
Journal Article
Closed access
PDF file
DMDeok‐Bog. Moon
Deok‐Bog. Moon
SLSung‐Gyu Lee
Sung‐Gyu Lee
SHShin Hwang
Shin Hwang
CAChul‐Soo. Ahn
Chul‐Soo. Ahn
KKKi‐Hun. Kim
Ki‐Hun. Kim
SHSu‐Min Ha
Su‐Min Ha
Simultaneous splenectomy (SSPX) in adult living donor liver transplantation (ALDLT) has definitely beneficial roles such as portal flow modulation in small‐for‐size graft and correction of hypersplenism‐related pancytopenia, and so on, but disastrous complications after SSPX often occur. For the first time, we devised unique and innovative splenic devascularization (SDV) procedure to alleviated untoward effects of SSPX but to maintain its benefits for the indicated patients. From April 2013 to December 2014, 520 recipients underwent ALDLT, and the SSPX and SDV were simultaneously performed in 62 (11.9%) and 61 (11.7%) patients respectively. The most common indication was hypersplenism‐related pancytopenia (n=101), small‐for‐size graft (n=14), HCV (n=7), and splenic artery aneurysm (n=1). Postoperative small‐for‐size graft syndrome (SFSS) was absent in both SSPX and SDV, and preoperative pancytopenia was improved in both groups since postoperative 1 week, although SSPX was more substantial than SDV. Preoperative splenic volume (706.2 ± 282.9 mL) after SDV significantly decreased to 425.5 ± 204.4 mL on 1 month, respectively. In contrast to SDV, SSPX resulted in longer operation time and higher incidence of postoperative complications including mortality. In conclusion, SDV can replace SSPX during ALDLT without hampering its beneficial roles seriously, but get rid of splenectomy‐related lethal complication.

28 February 2022 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
SKSang-Hoon Kim
Sang-Hoon Kim
SHShin Hwang
Shin Hwang
GSGi-Won Song
Gi-Won Song
DJDong-Hwan Jung
Dong-Hwan Jung
DMDeok-Bog Moon
Deok-Bog Moon
HYHee Chul Yu
Hee Chul Yu
Sang-Hoon Kim, Shin Hwang, Gi-Won Song, Dong-Hwan Jung, Deok-Bog Moon, Jae Do Yang, Hee Chul Yu. Ann Hepatobiliary Pancreat Surg 2022;26:58-68. https://doi.org/10.14701/ahbps.21-108

9 February 2022 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
JYJung Min Youn
Jung Min Youn
SHShin Hwang
Shin Hwang
CAChul-Soo Ahn
Chul-Soo Ahn
DMDeok-Bog Moon
Deok-Bog Moon
THTae-Yong Ha
Tae-Yong Ha
SHSeung-Mo Hong
Seung-Mo Hong